data provide direct evidence that the PD-1/PD-L1 pathway is involved in CD8+ T-cell dysfunction in non-small cell lung cancer patients

Studies indicate that PD-1/PD-L1 antibodies, considered as drug of the year 2013, showed results in melonoma, renal cancer and lung cancer.

PD-1 inhibitor nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer.

High PD-1 expression is Correlated with Non-Small Cell lung cancer.

Immune checkpoint inhibitors, particularly those targeting PD-1 and PD-L1 are clinically active for the treatment of lung cancer and represent an exciting step forward in lung cancer therapy.

anti-CTLA-4 and anti-PD-1 immune checkpoint blockade (ICB) monoclonal antibodies are becoming parts of the oncologists' armamentarium against melanoma and non small-cell lung cancer (NSCLC).

Data suggest signaling via CD279/PDCD1 and its ligand CD274/PD-L1 is effective chemotherapy target in non-small cell lung cancer; PD-L1 is best currently available immunohistochemistry biomarker for response to immune checkpoint inhibitors. [REVIEW]

Surface expression of PD-1 on CD4+ T cells has a prognostic value in non-small cell lung cancer patients, as high expression of PD-1 is associated with a shorter progression-free survival and overall survival.

Of several immunotherapies being investigated, antibodies that target the programmed cell death protein-1 (nivolumab and pembrolizumab) and cytotoxic T-lymphocyte antigen-4 (ipilimumab) immune checkpoint pathways are among the most promising for patients with Small cell lung cancer (SCLC), and are the focus of this review.

We identified that there are significant differences between the tumor microenvironment of paired primary lung cancers and brain metastases. When physicians decide to treat patients with lung cancer with a PD-1 or PD-L1 inhibitor, they must do so in the context of the spatial and temporal heterogeneity of the tumor microenvironment

PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in non-small cell lung cancer.

The incidence of PD-1 inhibitor-related pneumonitis was higher in non-small cell lung cancer and renal cell carcinoma during combination therapy. These findings contribute to enhance awareness among clinicians and support further investigations to meet the clinical needs

cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of small cell lung cancer cells under cisplatin selection.

PD1 underexpression is associated with Non-Small-Cell lung cancer.

High PD-1 expression is associated with Non-Small-Cell lung cancer.

The expressions of PD-1 and PD-L1 may be associated with the occurrence and development of pulmonary carcinoids.

This work provides evidence that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti-PD-1/PD-L1 immunotherapy

PD-1 and PD-L1 protein expression and their correlation with tumor-in fi ltrating lymphocytes (TILs), and association with survival in non-small cell lung cancer, were examined.

Significant differences in the CpG-methylation patterns between tumor tissues and matched controls were observed for PDCD1 showing a decreased methylation of this gene in non-small cell lung cancer patients. expression studies confirmed that hypomethylation also resulted in increased expression of PDCD1.

An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer

this study demonstrated that PD-1 may involve in lymph nodes metastasis and promote the understanding of the mechanism of immunotherapies in the non-small cell lung cancer

High PD-1 expression is associated with lung adenocarcinoma.

Healthy donor-derived double negative T (DNT) cells significantly inhibited the growth of late-stage lung cancer xenografts, which was further augmented by anti-PD-1 through increased DNT cell tumor infiltration. This study supports the use of DNT cells for adoptive cellular therapy against lung cancer either alone or in combination with anti-PD-1.

Study demonstrated that the presence of necrosis correlates with higher PD-L1 expression of tumor cells and PD-1 expression of immune cells in lung adenocarcinoma (LADC). Further studies are required to determine the predictive value of this observation in LADC patients receiving immunotherapy.

Therapeutic indications and predictive factors for immunotherapy with anti-PD-1 and anti-PD-L1 antibodies in non-small cell lung cancer (NSCLC) patients are very diverse. expression of PD-L1 on tumor cells and tumor mutations burden are neither the only nor the perfect predictors for immunotherapy.

expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell lung cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

study indicated that the PD-1 gene and the SNPs on it could be used as markers for distinguishing lung adenocarcinoma staging in the Northeast Han population

Stromal PD-1(+) tumor-associated macrophages predict poor prognosis in lung adenocarcinoma.

circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma.

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.

Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.

TIGIT presents earlier expression dynamic than PD-1 in activated CD8(+) T cells and is upregulated in non-small cell lung cancer patients.

CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling pathway in Non-Small Cell lung cancer.

Anti-PD-1/PD-L1 therapy inhibited CMT167 orthotopic lung tumors by 95%. .Silencing PD-L1 expression in CMT167 cells resulted in smaller orthotopic tumors that remained sensitive to anti-PD-L1 therapy, whereas implantation of CMT167 cells into PD-L1(-) mice blocked orthotopic tumor growth, indicating a role for PD-L1 in both the cancer cell and the microenvironment.

Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis.

TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.